U
BIIB icon

UBS’s Biogen BIIB Stock Holding History

UBS’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3.75M Buy
11,325
+2,225
+24% +$734K ﹤0.01% 2311
2014
Q2 		$2.87M Sell
9,100
-400
-4% -$120K ﹤0.01% 2526
2014
Q1 		$2.91M Sell
9,500
-26,400
-74% -$8.38M ﹤0.01% 2398
2013
Q4 		$10M Sell
35,900
-3,200
-8% -$828K 0.01% 1244
2013
Q3 		$9.41M Sell
39,100
-700
-2% -$157K 0.01% 1179
2013
Q2 		$8.56M Buy
+39,800
New +$8.5M 0.01% 1156

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

UBS's BIIB Position: Q3 2014 in Review

UBS increased its Biogen (BIIB) stake by 8.3% in Q3 2014, buying an estimated $4.28M and bringing the position to 168,877 shares worth $55.9M. The position accounts for 0.04% of the portfolio, ranked #465.

UBS first reported a position in BIIB in Q2 2013 and has held it in 6 quarters since. 818 funds tracked by Wall St. Rank hold BIIB as of Q3 2014.

  • UBS held 168,877 shares of Biogen worth $55.9M as of Q3 2014.
  • UBS bought 12,990 Biogen shares in Q3 2014, an estimated $4.28M.
  • Biogen made up 0.04% of UBS's portfolio in Q3 2014, its #465 holding.
  • UBS first reported a position in Biogen in Q2 2013 and has held it in 6 quarters since.
  • 818 funds tracked by Wall St. Rank held Biogen as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.